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Abstract
The fundamental objective for health research is to determine whether changes should be made to
clinical decisions. Decisions made by veterinary surgeons in the light of new research evidence are
known to be influenced by their prior beliefs, especially their initial opinions about the plausibility
of possible results. In this paper, clinical trial results for a bovine mastitis control plan were evaluated
within a Bayesian context, to incorporate a community of prior distributions that represented a
spectrum of clinical prior beliefs. The aim was to quantify the effect of veterinary surgeons’ initial
viewpoints on the interpretation of the trial results.
A Bayesian analysis was conducted using Markov chain Monte Carlo procedures. Stochastic models
included a financial cost attributed to a change in clinical mastitis following implementation of the
control plan. Prior distributions were incorporated that covered a realistic range of possible clinical
viewpoints, including scepticism, enthusiasm and uncertainty. Posterior distributions revealed
important differences in the financial gain that clinicians with different starting viewpoints would
anticipate from the mastitis control plan, given the actual research results. For example, a severe
sceptic would ascribe a probability of 0.50 for a return of <£5 per cow in an average herd that
implemented the plan, whereas an enthusiast would ascribe this probability for a return of >£20 per
cow. Simulations using increased trial sizes indicated that if the original study was four times as
large, an initial sceptic would be more convinced about the efficacy of the control plan but would
still anticipate less financial return than an initial enthusiast would anticipate after the original study.
In conclusion, it is possible to estimate how clinicians’ prior beliefs influence their interpretation of
research evidence. Further research on the extent to which different interpretations of evidence result
in changes to clinical practice would be worthwhile.
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1. Introduction
Much research in health aims to understand the processes related to disease, and, ultimately,
to improve health interventions in populations and clinical management of individual patients.
Results from such research are of greatest value when findings translate into improvements in
health and welfare. For new research to be worthwhile in terms of changing clinical decisions,
the clinical beliefs (‘clinical priors’) of the decision-makers need to be understood and taken
into account. This is important because the inferences made by each individual in the light of
a particular clinical trial will be influenced by their prior beliefs or degree of scepticism about
the plausibility of different possible results (Chaloner and Rhame, 2001; Spiegelhalter et al.,
2004a). Whilst it is important to note that an individual clinician’s decision to change their
approach to disease control is complex (and may depend on a variety of psychological and
circumstantial factors, as well as the perceived cost or health benefit (Crosskerry, 2005)),
investigation of the influence of prior beliefs is an important element of understanding this
decision process.
The fact that there are prior beliefs in medicine is well documented (e.g. Fallowfield et al.,
1997; Peto and Baigent, 1998; Spiegelhalter et al., 2004a; Henry et al., 2006). Such beliefs
have been used to predict and understand the decision making process of medical physicians
(Parmar et al., 1994; Brophy and Joseph, 1995; Harrell and Shih, 2001). Documenting prior
beliefs before undertaking clinical trials is useful to gauge the likely response of clinicians to
possible trial outcomes (and therefore whether clinical decision-making will change) and also
to aid in sample size calculations–the strength of evidence required differs depending on the
degree of scepticism at the outset (Kadane, 1994; Parmar et al., 1994; Chaloner and Rhame,
2001). However, prior distributions are not necessarily pre-specified or unique and can be used
post hoc, to assess how research results may be interpreted, conditional on varying personal
viewpoints (Spiegelhalter et al., 2004a).
In veterinary medicine, little is known of the heterogeneity in clinical beliefs of veterinary
surgeons, although this will fundamentally affect interpretation of research evidence and
approaches to disease management. The use of a ‘community of priors’ has been proposed by
Kass and Greenhouse (1989) to describe a spectrum of realistic viewpoints that should be
considered when interpreting new evidence.
Bayesian methods are particularly suited to the incorporation of prior beliefs in a probabilistic
decision-theoretic context (Berry and Stangl, 1996; O’Hagan and Luce, 2003) and have some
advantages over frequentist approaches that include the following, a straightforward
framework for predicting future events and the ability to include information, with associated
uncertainty, from a variety of sources (Berry, 1993; Spiegelhalter et al., 2004a).
The purpose of the current research was to re-evaluate the results of a clinical trial for a control
plan for bovine mastitis (Green et al., 2007). A community of priors was incorporated, within
a Bayesian context, to represent a spectrum of prior opinions of clinicians. The aim of the
research was to assess the variability in clinical interpretation that could arise from veterinary
surgeons with different prior viewpoints.
2. Method
2.1. Description of the original clinical trial
The original research comprised a randomised clinical trial for a mastitis control plan on 52
dairy herds and has been described in detail in Green et al. (2007). A brief outline of the methods
and results is presented here. In January 2004, a database administered by National Milk
Records (NMR, Chippenham, UK) was used to identify and randomly select dairy herds with
Green et al. Page 2
Prev Vet Med. Author manuscript; available in PMC 2009 August 28.
U
KPM
C
 Funders G
roup Author M
anuscript
U
KPM
C
 Funders G
roup Author M
anuscript
a recorded incidence rate of clinical mastitis >35 cases per 100 cows during the previous 12
months. Selection was made from herds situated throughout England and Wales. Herds were
randomly allocated to one of two groups. The first group had an intervention–a mastitis control
plan implemented (this was a holistic control scheme devised from research literature) whilst
the second group were treated as control herds. The first stage of the control plan was to assess
the patterns and types of mastitis in each herd. The second stage was to compare existing farm
control measures with those in the control plan to highlight the measures not used by the farmer.
A level of importance was attached to each control measure to determine a priority for
implementation and a set of up to 20 final recommendations were made to each farmer in the
intervention group. Compliance with the control plan was measured and estimated as the
proportion of recommendations made that were actually implemented by the farmer during the
1 year study period. A simple categorisation was used for compliance, this was a score of one
given when less than one-third of recommendations were applied, two when between one and
two-thirds were applied and three when greater than two-thirds were applied.
A response variable used to assess efficacy of the control plan was the change in incidence rate
of clinical mastitis between year 1 (the 12 months before the intervention was carried out) and
year 2 (the 12 months following the date of intervention) expressed as a proportion of the year
1 incidence rate of clinical mastitis. The null hypothesis for the study was that there would be
no difference in the change in incidence rate of clinical mastitis between intervention farms
that implemented the plan (n = 26) and control farms that did not (n = 26). The alternative
hypothesis was that there would be a difference between treatment groups in the mean
proportional change of clinical mastitis of ≥0.20 and conventional sample size estimates were
undertaken with a power set at 0.8 and significance probability at 0.05. The original analysis
was conducted within a frequentist framework and the relevant results were as follows:
1. Proportional change in incidence rate of clinical mastitis for intervention herds versus
control herds = −0.20 (SE = 0.09), p < 0.05.
2. Proportional change in incidence rate of clinical mastitis for compliance score 3 herds
versus control herds = −0.39 (SE = 0.14), p < 0.01.
2.2. Bayesian models
The two models from which these results were calculated in the original study were replicated
using the same data, and placed within a Bayesian framework with specification of prior
distributions for model parameters. Model parameter posterior distributions were estimated
using Markov chain Monte Carlo using the WinBUGS software package (Version 1.4,
Spiegelhalter et al., 2004b).
The models considered for the current analysis were
Model 1
Model 2
where yi: proportional change in incidence rate of clinical mastitis in herd i; β0: model intercept;
IFi: covariate to identify intervention farms,; β1: coefficient representing the mean proportional
change in incidence rate of clinical mastitis for intervention herds compared to control herds.;
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IRCMyr1i: covariate to account for starting incidence rate of clinical mastitis in herd i; β2 and
β6: coefficients for year 1 IRCM; C3i, C2i, C1i: covariates for herds of compliance categories
3, 2 and 1 respectively compared to control herds.; β3, β4 and β5: coefficients for compliance
categories 3, 2 and 1 respectively.; e1ii and e2i: residual terms to reflect unexplained variation
between herds with variance  and  in Models 1 and 2, respectively.
Models were run with three Markov chains and the effect of different chain starting values on
model parameters was investigated but not found to influence posterior estimates. Model
convergence was examined using informal visual assessment of the chains (Gilks et al.,
1996) and the Gelman-Rubin convergence diagnostic (Brooks and Gelman, 1998). All of the
MCMC analyses reported in the current paper used a burn-in of at least 2000 iterations and all
models converged well ahead of the end of this burn-in. Analysis was then based on an
additional 20,000 iterations.
2.3. Prior distributions
A range of Gaussian prior distributions were assessed for the fixed effect parameters β0, β2,
β4, β5 and β6, to investigate their influence on β1 (Model 1) and β3 (Model 2). Gaussian
distributions were investigated with a mean of 0.5, 0, or −0.5 and a variance of 10,000 or 0.25.
No substantive differences were identified in model results and the distribution (mean = 0,
variance = 10,000) was used for the final models. Several alternative priors for the distributions
of e1i and e2i were investigated (Uniform (0, 5) or Uniform (0, 1) for the standard deviations
or inverse Gamma (0.01, 0.01) for the variances) but the choice had little effect on the other
parameter estimates and Uniform (0, 5) priors were used in the final models. Six different prior
distributions were incorporated for the coefficients of interest, β1 (Model 1) and β3 (Model 2);
the aim was to choose priors that would cover a realistic and reasonable range of clinical opinion
and that could represent views sensibly held by clinicians. This community of priors is
described in Tables 1 and 2.
2.4. Financial evaluation
To further elucidate possible differences in interpretation of the clinical trial data between
clinicians with different prior beliefs, a financial evaluation was carried out as follows. Models
were extended to include a financial gain (or loss) attributed to the anticipated change in clinical
mastitis (£s per cow in the herd per year) conditional on the clinical trial data and the prior
distributions. The estimated cost of a case of clinical mastitis was based on a recent publication
of disease costs in UK dairy herds (Esslemont and Kossaibati, 2002). The mean estimated cost
per case was a combination of treatment costs (including veterinary time), herdsman time,
discarded milk, reduced subsequent milk yield, severity of disease and risk of culling or death
(Esslemont and Kossaibati, 2002). Milk price has recently increased in the UK, however, and
there is currently some variation between farms. Therefore a distribution for milk price was
included in the calculation, based on current prices, with a mean of £0.25/l and standard
deviation of £0.01/l. Other financial values remained as originally reported (Esslemont and
Kossaibati, 2002). The resultant cost of a case of clinical mastitis was normally distributed
with mean £212.30 and standard deviation £5.44. The financial gain anticipated from
implementing the control plan on a herd with an assumed incidence rate of clinical mastitis of
0.5 cases per cow per year (the approximate mean value for UK farms (Bradley et al., 2007))
was estimated from the posterior (predictive) distribution of β1 (the proportional reduction in
clinical mastitis estimated from Model 1) and the cost per case of clinical mastitis:
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The distribution of the anticipated financial gain was estimated for each prior distribution of
β1 (Table 1), using MCMC, by evaluating 20,000 iterations after model convergence. To obtain
an estimate for the financial returns anticipated in a fully complying herd, the procedure was
repeated using β3 and Model 2.
The probabilities of obtaining financial returns greater or equal to specified financial levels
(between £0 and 50 per cow in the herd per year) were estimated for each prior distribution of
β1 and β3. This was carried out within the MCMC procedure as follows: at each iteration, an
indicator variable was set to 1 when the model predicted the financial return was greater than
a specified value and otherwise to 0. The mean value of this indicator over the 20,000 iterations
after convergence provided an estimate of the probability of exceeding the specified financial
return, a method similar to that described for Monte Carlo P values (Marshall and Spiegelhalter,
2003).
2.5. Investigations of posterior distributions and simulations of increased trial sizes
The heterogeneity in the posterior distributions of β1 (Model 1) was further explored by
including a wider variety of combinations of values for both the prior mean (range 0 to −0.3)
and prior standard deviation (range 0.001-100). Modelling procedures were as described above,
and the mean posterior values for β1, for different values of prior mean and standard deviation,
were displayed graphically.
MCMC simulations were carried out to predict the possible effect of increasing the size of the
original clinical trial on the inferences of clinicians with originally sceptical or originally
enthusiastic prior beliefs. Simulations of larger sized trials were conducted by replicating the
original dataset by a factor of two, three and four times. Therefore, the distribution of the data
and model coefficients remained the same but the uncertainty associated with parameter
estimates was reduced. Posterior distributions for β1 were estimated for each simulated trial of
increased size, incorporating either a sceptical or enthusiastic prior distribution for β1. The
probability of anticipated financial changes attributed to changes in clinical mastitis were
calculated for each simulated trial, as described in Section 2.4, and displayed graphically.
3. Results
3.1. Posterior distributions of β1 and β3
The posterior distributions of β1 from Model 1 are presented in Table 3. With the inclusion of
the vague prior distribution for β1, the resulting posterior distribution had very similar
characteristics to the original frequentist estimates for β1. The probabilities for an anticipated
financial saving from a reduced incidence of clinical mastitis were 0.85 for a return of at least
£10 per cow in the herd and 0.54 for a return of at least £20 per cow in the herd. The sceptical
prior resulted in a posterior mean estimate for β1 of −0.10, half way between the sceptical prior
mean and the original frequentist estimate for β1, indicating that a clinician with this sceptical
viewpoint would effectively discount the clinical trial results by approximately 50% compared
to the frequentist interpretation of the data. The very sceptical prior was altered very little by
the trial data, the posterior mean of −0.04 being one-fifth of the original frequentist estimate
for β1 and thus these data would make only a small impact on a clinician with such a large
degree of scepticism. The cautious sceptic (Table 1), would be more convinced by the trial
results, the posterior mean estimate for β1 being −0.13. This was similar to the posterior mean
of −0.15 estimated with a prior belief that β1 was at the mid-point between the sceptical and
enthusiastic priors. The enthusiastic prior resulted in a similar mean posterior estimate to the
vague prior (−0.20), but with a reduced standard deviation (0.07) indicating a greater certainty
in the posterior mean if this prior view was held. The posterior mean for β1 estimated using a
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very enthusiastic prior was −0.28 and thus remained closer to this prior distribution mean than
the original frequentist mean estimate.
The characteristics for the posterior distributions of β3 estimated in Model 2 are presented in
Table 4. Similar patterns were identified between the different choices of prior as for β1. It was
particularly notable that whilst the sceptical prior resulted in a posterior distribution indicating
a reasonably large anticipated reduction in clinical mastitis (posterior mean−0.21, standard
deviation = 0.11), the original trial data would be insufficient to convince clinicians with views
represented by the very sceptical prior distributions, that the control plan would be very
effective, even in herds that fully complied (posterior mean = −0.04, standard deviation = 0.05).
3.2. Financial evaluations
The anticipated financial returns estimated from Models 1 and 2 are presented in Figs. 1 and
2. Clinicians with beliefs represented by any of the prior distributions, except the very sceptical
category, would anticipate a gain of ≥£10 in this “average” herd that undertook the control
plan with a probability of ≥0.50. The posterior probability of a gain ≥£10 varied from 0.55 for
the sceptical prior distribution to 0.99 for the very enthusiastic prior.
There was considerable variation in the posterior probability of achieving a gain of at least £20
per cow in the herd dependent on the different prior distributions. The very sceptical prior
resulted in a posterior probability of virtually zero whereas the vague or enthusiastic priors
resulted in a posterior probability greater than 0.50. A clinician with a view represented by the
very enthusiastic prior view would anticipate a gain ≥£20 as being almost certain with a
probability approaching 1.0.
Taken as a whole, results from Model 1 (Fig. 1) demonstrated that the probability of different
financial gains varied greatly with different prior distributions. This variability indicates that,
in light of the clinical trial data, clinicians could differ widely in their approach to implementing
the plan, some anticipating considerably more financial return than others.
The pattern of results was broadly similar when herd compliance with the control plan was
considered in Model 2 (Fig. 2), although with higher anticipated financial returns. Parameter
estimates revealed that clinicians with beliefs represented by any of the prior distributions,
except the very sceptical prior, would anticipate a 0.50 probability of a gain of more than £22
per cow in a herd that undertook and fully complied with the control plan, compared to a non-
participant. However, there was considerable variability in the anticipated probability of
achieving minimum gains in the region of £20-40 per cow in the herd (Fig. 2), dependent on
prior clinical beliefs, again indicating that the trial data are likely to lead to different clinical
interpretations dependent upon different initial viewpoints.
3.3. Further assessment of the prior distribution characteristics
As illustrated in Fig. 3, the mean posterior value of β1 varied to a large extent with both the
mean and standard deviation of the prior distribution of β1. The posterior mean tended towards
the value of the prior mean as the prior standard deviation decreased and tended towards −0.20
as the prior standard deviation increased. A given posterior mean value (for example −0.15)
could result from a prior distribution with a mean close to that posterior mean (e.g. −0.15) with
a relatively small standard deviation, or from a prior mean closer to zero, and a relatively larger
standard deviation.
3.4. Simulations of increased sized trials
Simulations of anticipated financial returns with different theoretical sizes of trial are
summarised in Fig. 4. Simulations using the sceptical prior distribution demonstrated that the
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anticipated financial gain gradually increased (curves moved to the right) and the variation of
the posterior distribution decreased (curves became steeper) as trial size increased. However,
the increase in anticipated financial gain became proportionately less as the new data became
less influential in comparison to the existing information. With a clinical trial four times the
size of the original, an initial sceptic would consider that there was a comparable probability
(0.93) of a financial gain of at least £10 per cow in the herd, to an initial enthusiast after the
original sized clinical trial. However, after a study size four times larger than the original, an
initial sceptic would still attribute a lower probability (0.28) than the initial enthusiast would
attribute after the original study (0.58), that a minimum gain of £20 per cow would be achieved.
Simulations of increased trial sizes using the enthusiastic prior as the starting point (Fig. 5)
demonstrated that anticipated financial gains would change very little with the increased
information, although the clinician with this original belief would become more certain of their
anticipated financial return with the additional information.
4. Discussion
The results suggest that a clinician’s prior view will make a fundamental impact on how the
clinical trial data for this mastitis control plan are interpreted. An initial sceptic, when presented
with this evidence would anticipate a reduction in clinical mastitis approximately half that of
the initially enthusiastic clinician. This translates into large differences in anticipated financial
gains from reduced clinical mastitis, often in the region £5 and £20 per cow in the herd (Figs.
1 and 2). The differences in clinical interpretation and anticipated financial return dependant
on prior viewpoints are of a magnitude that would make important material differences in
practice and are likely to influence the assessment of when the plan is cost effective and
therefore recommended. The results also illustrate why a conventional ‘significant’ result may
provide an insufficient strength of evidence to change the clinical approaches of some more
sceptical clinicians.
The costs of implementing this mastitis control plan will vary between herds depending on the
management changes required (Green et al., 2007), but the annual costs are likely to be in the
region £5 to £50 per cow in the herd. For a 100 cow herd this equates to a variation in total
implementation costs of £500 to £5000 per annum, reflecting, for example, differences between
small changes to current management or a capital investment with repayment over several
years. Therefore differences in anticipated financial return of £5 to £20 per cow, depending on
a clinicians view, will be important in determining whether the plan is implemented, and
therefore could lead to different clinical decisions in the same farm circumstances.
An individual clinician’s decision to change their approach to disease control, however, is
complex and will depend on a variety of psychological factors, as well as the perceived cost
or health benefit. A rational decision has been defined as one that meets four criteria (Hastie
and Dawes, 2001): it is based on the decision makers current state (physiological,
psychological, financial, social and emotional), on the possible consequences of the choice, on
the logical probability of different outcomes and is adapted according to the value placed on
each possible outcome. Therefore, the situation, cognitive dispositions and personality of a
clinician will influence how decisions are made (Crosskerry, 2005) and this means that
individual veterinary clinicians with the same prior beliefs and presented with the same
research evidence may make different judgements. Factors such as the veterinary surgeon-
client relationship, the farm situation (such as the financial state), the value attributed to non-
financial benefits (such as cow welfare) will influence decision-making alongside the current
mastitis situation and anticipated return on investment from implementing the plan. Whilst
different prior beliefs can greatly affect the interpretation of a single piece of research evidence,
more research would be useful to investigate and quantify other aspects of the decision
processes in farm animal health.
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Results from the current study confirm the importance of both the magnitude (location) of a
prior belief and the certainty with which the view is held (Fig. 3). When the certainty of a prior
belief declines, the influence of the data increases and the posterior mean tends towards the
likelihood of the data. Therefore, to assess a clinician’s final belief, in light of new evidence,
it is important to establish not only the central location of their prior view but also the certainty
with which it is held, and methods have been described to elicit these quantities (O’Hagan et
al., 2006). The graph of different prior distribution means and standard deviations in relation
to subsequent posterior distribution means (Fig. 3) illustrates prior distribution standard
deviations varying from very small (0.01) to relatively large (2.0). In reality, such extreme
clinical views would be unlikely. It seems improbable that a clinician would have a belief with
a 95% credibility interval as small as ±0.02 around the estimated mean (a change in mastitis
of only ±2% of the initial level). Similarly, a prior standard deviation of 1.00 would mean that
a clinician was so uncertain that there was a 95% credibility interval of approximately ±2.00
around the mean effect (a change in mastitis of ±200% of the initial level), this would appear
to be greater than could be reasonably anticipated. It is likely that most clinical prior beliefs
would have a standard deviation in the region 0.05-.3 and thus the region of the graph (Fig. 3)
within this range probably contains the most realistic representation of the relationship between
plausible clinical prior distributions and the posterior mean.
The vague prior distributions used in these analyses for the fixed effects β1 and β3 are often
described as “non-informative” or “reference” priors (Spiegelhalter et al., 2004a) and often
will result in a posterior distribution with characteristics similar to the frequentist estimates
(Gurrin et al., 2000). However, it is hard to ascribe a realistic, rational clinical meaning to this
prior distribution since such an uninformed view would seem to be almost impossible to be
held by a clinician. Therefore, whilst it is useful in terms of allowing the data to have “an
overriding influence” on the posterior distribution, it is of limited value when trying to evaluate
the likely interpretation of clinicians in the field. Since Bayesian philosophy essentially
concerns the updating of personal beliefs in the light of new evidence, the use of vague,
unrealistic prior distributions has understandably been questioned (Senn, 2007).
The value of assessing the effect of sceptical priors in clinical trials is illustrated in the current
study by the important clinical differences that would arise in interpretation of these mastitis
trial data. Sceptical priors are also useful to estimate sample sizes for clinical trials (Chaloner
and Rhame, 2001) and if scepticism is known to be common, then it is important to design a
study that can convince sufficient members of the relevant population. In the current study,
simulations of clinical trials of increased size identified that with more data, a clinician with
an initial sceptical view would gradually become more convinced of the efficacy of the control
plan. If such a sceptical view is very prevalent in the population of veterinary surgeons, then
larger studies would be important to provide sufficient evidence to convince these clinicians
that the control plan could be worthwhile.
Bayesian methods are particularly useful to calculate probabilities that may be extrapolated
directly to clinical practice (Burton et al., 1998; Lilford et al., 1995) and this research provides
an illustration in veterinary medicine. Although the testing of a variety of prior opinions in
Bayesian analyses has been strongly recommended to demonstrate how new data would add
to the range of currently held views (Koch, 1991; Hughes, 1991; Spiegelhalter et al., 2004a)
this type of analysis has been rarely reported in the medical or veterinary literature. However,
it is necessary to understand clinical inferences and the decision-making process, beyond
simply providing new evidence, if research is going to have a widespread impact on animal
health. This is particularly true in veterinary medicine in which there is little overall national
strategy for many diseases of dairy cows and in which many decisions on herd health are taken
by individual practitioners rather than being set by a general health policy. Research to quantify
the population structure of veterinary beliefs for mastitis control and other aspects of herd
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health management would be very welcome to improve the understanding of the diversity of
clinical approaches exhibited by veterinary surgeons. Knowledge of the degree and distribution
of scepticism and enthusiasm would help to inform future research both in terms of research
areas most needed and the strength of evidence that would be necessary to convince clinicians
that changing approaches could be beneficial.
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Fig. 1.
An illustration of the probability of the anticipated overall financial gains from implementing
the mastitis control plan estimated from Model 1, conditional on specified prior distributions
(Table 1) and the clinical trial data.
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Fig. 2.
An illustration of the probability of anticipated financial gains from implementing the mastitis
control plan on farms that fully comply, estimated from Model 2, conditional on the specified
prior distributions (Table 2) and the clinical trial data.
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Fig. 3.
Graphical illustration of the variation of the prior mean and standard deviation, and the posterior
mean of β1, estimated from Model 1, conditional on the clinical trial data.
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Fig. 4.
An illustration of the probability of the anticipated overall financial gains from implementing
the mastitis control plan estimated from Model 1, using the original trial data and three
simulated trials of increased size that incorporated the sceptical prior (Table 1).
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Fig. 5.
An illustration of the probability of the anticipated overall financial gains from implementing
the mastitis control plan estimated from Model 1, using the original trial data and three
simulated trials of increased size that incorporated the enthusiastic prior (Table 1).
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